195 related articles for article (PubMed ID: 38429446)
1. A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.
Tomita U; Ishimoto Y; Ri M; Kawase Y; Hizukuri Y; Maru C; Nanai K; Nakamura R; Nakayama M; Oguchi-Oshima K; Sumi H; Ohtsuka T; Iida S; Agatsuma T
Sci Rep; 2024 Mar; 14(1):5135. PubMed ID: 38429446
[TBL] [Abstract][Full Text] [Related]
2. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
[TBL] [Abstract][Full Text] [Related]
3. Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.
Kodama T; Kochi Y; Nakai W; Mizuno H; Baba T; Habu K; Sawada N; Tsunoda H; Shima T; Miyawaki K; Kikushige Y; Mori Y; Miyamoto T; Maeda T; Akashi K
Mol Cancer Ther; 2019 Sep; 18(9):1555-1564. PubMed ID: 31270154
[TBL] [Abstract][Full Text] [Related]
4. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
5. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
[TBL] [Abstract][Full Text] [Related]
7. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
8. BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma.
Liu Y; Zhou YQ; Nie L; Zhu SS; Li N; Wu ZH; Wang Q; Qi J; Wu BY; Chen SQ; Wang HB
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136320
[TBL] [Abstract][Full Text] [Related]
9. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H
Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117
[TBL] [Abstract][Full Text] [Related]
10. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
11. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
12. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
13. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
Hipp S; Tai YT; Blanset D; Deegen P; Wahl J; Thomas O; Rattel B; Adam PJ; Anderson KC; Friedrich M
Leukemia; 2017 Aug; 31(8):1743-1751. PubMed ID: 28025583
[TBL] [Abstract][Full Text] [Related]
14. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau P; Touzeau C
Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
17. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
18. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
[TBL] [Abstract][Full Text] [Related]
19. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Xia J; Li Z; Xu K
J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
